Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 2196  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 »   Next article
 »   Previous article
 »   Table of Contents

 Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded4    
    Comments [Add]    

Recommend this journal


Year : 2022  |  Volume : 70  |  Issue : 2  |  Page : 633--637

The Influence of ADORA2A on Levodopa-Induced Dyskinesia

1 University of Health Sciences, Erenkoy Mental Health and Neurological Disorders Training and Research Hospital, Neurology Department, Istanbul, Turkey
2 Bahcesehir University Medical Faculty, Neurology Department, Istanbul, Turkey
3 Yeditepe University Medical Faculty, Genetics Department, Istanbul, Turkey

Correspondence Address:
Dr. Buse Cagla Ari
Department of Neurology, University of Health Sciences, Erenkoy Mental Health and Neurological Disorders Research and Training Hospital; Erenkoy Ruh ve Sinir Egitim ve Arastirma Hastanesi Noroloji Yatan Hasta Servisi, Sinan Ercan Cad. No: 29 34744 Kazasker – Kadikoy/Istanbul
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0028-3886.344646

Rights and Permissions

Background: Dopamine deficiency causes Parkinson's disease (PD), and on treatment, levodopa is the gold standard. Various drug-metabolizing enzymes and drug receptors are believed to be involved in prompting dyskinesias due to the extended usage of levodopa. Shreds of evidence in genomic studies have presented that ADORA2A receptor antagonism has beneficial outcomes to avoid these drug-induced side effects. Objective: The aim of this study was to study the polymorphisms of rs2298383, rs35060421, and rs5751876 in the ADORA2A in patients diagnosed as PD and describe their possible relationships with levodopa-induced dyskinesias (LID). Methods: One-hundred and seventy-two patients were recruited and separated as the study and the control group. DNA was achieved from peripheral venous blood, high resolution melting analysis, and reverse-transcriptase PCR was performed. Results: The allele differences among the groups were not statistically significant. Although it was not statistically significant, the rs35060421 allele was observed to repeat more frequently. However, we did not find an association between such polymorphisms of ADORA2A and LID. Conclusions: Although this result showed that a higher sample number might produce different results as possible, current results in the Turkish sample indicated that these alleles of ADORA2A might not be related to LID in patients.


Print this article     Email this article

Online since 20th March '04
Published by Wolters Kluwer - Medknow